market folly

Roberto Mignone's hedge fund firm Bridger Capital has filed a 13G with the SEC regarding their position in Pacific Biosciences of California (PACB).

Per the filing, Bridger now owns 5.1% of the company with over 4.46 million shares.  The filing was made due to activity on April 15th.  This is up from the 2.15 million shares they owned at the end of 2015.

Per Google Finance, Pacific Biosciences of California is "designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.."